Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,546 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,539 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04047693 | Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma | terminated | Phase 2 | 24 | Pusan National University Yangsan HospitalOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04053842 | Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy(IGPC-5) | completed | Phase 2 | 16 | Glenn BaumanOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04516135 | Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients With Metastatic Gynecologic Cancers | active not recruiting | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04752826 | BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) | recruiting | Phase 1 / Phase 2 | 250 | BioInvent International ABINDUSTRY | 7 | Sep 18, 2026 | clinicaltrials |
| NCT05048212 | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05327686 | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial(SAMURAI) | recruiting | Phase 2 | 240 | NRG OncologyOTHER | 4 | Sep 18, 2026 | clinicaltrials |
| NCT06085729 | Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) | recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06227065 | Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids(POLO) | not yet recruiting | Phase 2 | 28 | Hospital Centre Biel/BienneOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06678126 | Adaptive Versus Non-adaptive Radiotherapy and 2 Bladder Filling Instructions for Patients With Intermediate or High Risk Localized Prostate Cancer (ARP) | recruiting | Phase 2 | 104 | Scott TyldesleyOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06948552 | Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA | recruiting | Phase 2 | 10 | Henry Ford Health SystemOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07497919 | A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer | recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07650240 | Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial(SPARKLE) | recruiting | Phase 2 | 202 | Mayo ClinicOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07828704 | Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA | recruiting | Phase 2 | 10 | Henry Ford Health SystemOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)(MK-2870-001) | active not recruiting | Phase 1 / Phase 2 | 1,410 | Klus Pharma Inc.INDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT05003752 | Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer(Hypo-Combi) | active not recruiting | Phase 1 / Phase 2 | 40 | German Oncology Center, CyprusOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05011188 | FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 44 | Rahul AggarwalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05011383 | High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers(VA-BAT) | recruiting | Phase 2 | 51 | VA Office of Research and DevelopmentFED | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05021237 | Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy for Metastatic Cervical Cancer | completed | Phase 2 | 12 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05155046 | 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy | recruiting | Phase 2 | 130 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05239624 | Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer | recruiting | Phase 2 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05475171 | Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) | recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05616650 | Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor | recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05758688 | PROton Therapy for Post Surgical Treatment of GYNecologic Cancer(PROPS GYN) | recruiting | Phase 2 | 25 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06394570 | Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer(STAR-EV) | recruiting | Phase 1 / Phase 2 | 19 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06568094 | A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06582446 | Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)(HypoElect) | recruiting | Phase 2 | 30 | German Oncology Center, CyprusOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06733363 | A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer | recruiting | Phase 2 | 344 | Roswell Park Cancer InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07043972 | Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma | recruiting | Phase 2 | 55 | Fox Chase Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07049926 | Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) | recruiting | Phase 1 / Phase 2 | 140 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Sep 17, 2026 | clinicaltrials |
| NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | recruiting | Phase 1 / Phase 2 | 205 | Terremoto Biosciences Inc.INDUSTRY | 4 | Sep 17, 2026 | clinicaltrials |
| NCT07172802 | A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | GI Innovation, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07227415 | Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | recruiting | Phase 1 / Phase 2 | 224 | PfizerINDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT07332351 | Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial(TRIFECTA) | not yet recruiting | Phase 2 | 33 | University of WashingtonOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07667335 | Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT03543189 | Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy | completed | Phase 1 / Phase 2 | 44 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04273061 | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity(CAPTIV-8) | recruiting | Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04940299 | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | active not recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05155033 | Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma | recruiting | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05319015 | Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus | recruiting | Phase 2 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05796375 | Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance(ReplaceCysto) | recruiting | Phase 2 | 240 | White River Junction Veterans Affairs Medical CenterFED | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05831891 | Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma | active not recruiting | Phase 2 | 40 | RenJi HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06366347 | ALPINE: Maintenance Letrozole/Abemaciclib | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06873555 | A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | Heronova PharmaceuticalsINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07549256 | Cannabidiol for Pain Relief of Patients With End-stage mCRPC(ProCan) | recruiting | Phase 2 | 58 | Regionshospital NordjyllandOTHER_GOV | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07608718 | Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer | not yet recruiting | Phase 2 | 19 | Pedro Barata, MD, MScOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07718854 | Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer | recruiting | Phase 2 | 50 | Tufts Medical CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07822373 | A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer(PRESERVE) | not yet recruiting | Phase 2 | 25 | University of UtahOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02522715 | Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 37 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
Data updated 12 days agoSource updated Sep 18, 2026source: clinicaltrials